Insider Selling: Travere Therapeutics (NASDAQ:TVTX) Insider Sells $13,668.45 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 311 shares of the company’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total value of $13,668.45. Following the transaction, the insider owned 113,238 shares in the company, valued at $4,976,810.10. This trade represents a 0.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jula Inrig also recently made the following trade(s):

• On Tuesday, May 5th, Jula Inrig sold 2,174 shares of Travere Therapeutics stock. The shares were sold at an average price of $46.65, for a total value of $101,417.10.
• On Monday, May 4th, Jula Inrig sold 20,000 shares of Travere Therapeutics stock. The shares were sold at an average price of $45.00, for a total value of $900,000.00.
• On Wednesday, April 15th, Jula Inrig sold 1,018 shares of Travere Therapeutics stock. The shares were sold at an average price of $42.61, for a total value of $43,376.98.
• On Tuesday, April 14th, Jula Inrig sold 7,215 shares of Travere Therapeutics stock. The shares were sold at an average price of $41.93, for a total value of $302,524.95.

Travere Therapeutics Trading Down 0.1%

NASDAQ:TVTX opened at $42.60 on Friday. The firm has a market cap of $3.96 billion, a PE ratio of -185.21 and a beta of 1.13. The stock has a fifty day moving average price of $32.83 and a 200 day moving average price of $32.94. Travere Therapeutics, Inc. has a 12-month low of $13.88 and a 12-month high of $48.61. The company has a current ratio of 3.13, a quick ratio of 2.70 and a debt-to-equity ratio of 3.16.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Monday, May 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.29. The firm had revenue of $127.20 million during the quarter, compared to analyst estimates of $136.23 million. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.Travere Therapeutics’s revenue was up 55.6% compared to the same quarter last year. During the same period last year, the business posted ($0.47) earnings per share. Sell-side analysts anticipate that Travere Therapeutics, Inc. will post -0.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TVTX has been the subject of a number of recent research reports. Canaccord Genuity Group lifted their target price on Travere Therapeutics from $47.00 to $56.00 and gave the company a “buy” rating in a report on Tuesday, April 14th. Citigroup lifted their target price on Travere Therapeutics from $53.00 to $59.00 and gave the company a “buy” rating in a report on Tuesday. TD Cowen lifted their target price on Travere Therapeutics from $45.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday. Wells Fargo & Company raised their price target on Travere Therapeutics from $40.00 to $50.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Guggenheim raised their price target on Travere Therapeutics from $54.00 to $56.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Ten research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Travere Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $47.83.

Institutional Trading of Travere Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Swiss National Bank raised its stake in Travere Therapeutics by 0.6% in the first quarter. Swiss National Bank now owns 168,100 shares of the company’s stock valued at $4,994,000 after buying an additional 1,000 shares in the last quarter. Hillsdale Investment Management Inc. raised its stake in Travere Therapeutics by 2.9% in the first quarter. Hillsdale Investment Management Inc. now owns 182,320 shares of the company’s stock valued at $5,417,000 after buying an additional 5,100 shares in the last quarter. Fifth Third Bancorp purchased a new position in shares of Travere Therapeutics during the first quarter worth about $35,000. Hsbc Holdings PLC purchased a new position in shares of Travere Therapeutics during the first quarter worth about $11,788,000. Finally, Burney Co. purchased a new position in shares of Travere Therapeutics during the first quarter worth about $1,180,000.

Key Headlines Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Analysts remain bullish on Travere Therapeutics, with recent price target hikes to as high as $60 and continued Buy/Overweight ratings supporting the stock. Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $60.00
• Positive Sentiment: Q1 results beat EPS expectations and revenue grew 55.6% year over year, reinforcing the bullish analyst case and investor optimism. Travere Therapeutics, Inc. 2026 Q1 – Results – Earnings Call Presentation
• Positive Sentiment: Travere will present at several upcoming healthcare investor conferences, which could increase visibility and keep momentum around the stock. Travere Therapeutics to Participate at Upcoming Investor Conferences
• Neutral Sentiment: The company priced an upsized $475 million convertible senior notes offering to refinance 2029 notes, improving balance-sheet flexibility but creating potential future dilution. Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
• Neutral Sentiment: HC Wainwright trimmed earnings estimates slightly but kept a Buy rating and a $57 target, so the outlook remains supportive overall. Wells Fargo & Company Issues Positive Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price
• Negative Sentiment: Multiple insiders, including the CEO, CFO, directors, and executives, disclosed recent stock sales, which can create near-term concern even though many were tied to tax withholding and 10b5-1 plans. Jula Inrig Sells 20,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.